End-of-day quote
Nigerian S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
14.35
NGN
|
-.--%
|
|
-9.75%
|
-18.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
7,425
|
6,468
|
9,389
|
12,977
|
20,655
|
40,162
|
Enterprise Value (EV)
1 |
14,786
|
13,627
|
17,363
|
21,992
|
33,430
|
57,931
|
P/E ratio
|
-76.2
x
|
15.9
x
|
7.79
x
|
3.49
x
|
4.93
x
|
11.1
x
|
Yield
|
3.03%
|
4.84%
|
5.56%
|
8.04%
|
6.11%
|
3.43%
|
Capitalization / Revenue
|
0.46
x
|
0.46
x
|
0.51
x
|
0.42
x
|
0.51
x
|
0.76
x
|
EV / Revenue
|
0.91
x
|
0.97
x
|
0.95
x
|
0.71
x
|
0.82
x
|
1.09
x
|
EV / EBITDA
|
5.34
x
|
4.63
x
|
4.57
x
|
3.4
x
|
4
x
|
5.54
x
|
EV / FCF
|
-5.97
x
|
-8.58
x
|
-8.07
x
|
-20.7
x
|
-7.08
x
|
-14.3
x
|
FCF Yield
|
-16.8%
|
-11.6%
|
-12.4%
|
-4.83%
|
-14.1%
|
-6.99%
|
Price to Book
|
1.04
x
|
0.67
x
|
0.89
x
|
0.94
x
|
1.22
x
|
2.08
x
|
Nbr of stocks (in thousands)
|
1,650,000
|
2,294,996
|
2,294,996
|
2,294,996
|
2,294,996
|
2,294,996
|
Reference price
2 |
4.500
|
2.818
|
4.091
|
5.655
|
9.000
|
17.50
|
Announcement Date
|
3/31/19
|
5/21/20
|
3/31/21
|
4/1/22
|
4/1/23
|
4/3/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
16,230
|
14,062
|
18,276
|
30,861
|
40,634
|
53,050
|
EBITDA
1 |
2,770
|
2,942
|
3,796
|
6,474
|
8,352
|
10,458
|
EBIT
1 |
2,029
|
2,244
|
3,089
|
5,779
|
7,454
|
9,249
|
Operating Margin
|
12.5%
|
15.96%
|
16.9%
|
18.73%
|
18.35%
|
17.43%
|
Earnings before Tax (EBT)
1 |
160.9
|
575.7
|
1,773
|
4,718
|
5,781
|
5,917
|
Net income
1 |
-97.45
|
407.2
|
1,205
|
3,720
|
4,187
|
3,608
|
Net margin
|
-0.6%
|
2.9%
|
6.59%
|
12.05%
|
10.3%
|
6.8%
|
EPS
2 |
-0.0591
|
0.1774
|
0.5251
|
1.621
|
1.824
|
1.572
|
Free Cash Flow
1 |
-2,477
|
-1,587
|
-2,150
|
-1,061
|
-4,720
|
-4,050
|
FCF margin
|
-15.26%
|
-11.29%
|
-11.77%
|
-3.44%
|
-11.61%
|
-7.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1364
|
0.1364
|
0.2273
|
0.4545
|
0.5500
|
0.6000
|
Announcement Date
|
3/31/19
|
5/21/20
|
3/31/21
|
4/1/22
|
4/1/23
|
4/3/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
7,361
|
7,159
|
7,974
|
9,015
|
12,775
|
17,769
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.658
x
|
2.433
x
|
2.101
x
|
1.392
x
|
1.53
x
|
1.699
x
|
Free Cash Flow
1 |
-2,477
|
-1,587
|
-2,150
|
-1,061
|
-4,720
|
-4,050
|
ROE (net income / shareholders' equity)
|
-1.32%
|
4.85%
|
12%
|
30.6%
|
27.3%
|
19.9%
|
ROA (Net income/ Total Assets)
|
6.69%
|
6.87%
|
8.12%
|
12%
|
12.2%
|
11%
|
Assets
1 |
-1,457
|
5,929
|
14,847
|
31,077
|
34,190
|
32,755
|
Book Value Per Share
2 |
4.340
|
4.190
|
4.590
|
5.990
|
7.370
|
8.410
|
Cash Flow per Share
2 |
0.3300
|
0.1300
|
1.400
|
0.8500
|
0.9200
|
4.700
|
Capex
1 |
536
|
531
|
1,985
|
2,646
|
6,614
|
4,446
|
Capex / Sales
|
3.3%
|
3.77%
|
10.86%
|
8.57%
|
16.28%
|
8.38%
|
Announcement Date
|
3/31/19
|
5/21/20
|
3/31/21
|
4/1/22
|
4/1/23
|
4/3/24
|
Last Close Price
14.35
NGN Average target price
22.47
NGN Spread / Average Target +56.59% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.00% | 23.54M | | +20.61% | 43.18B | | +20.67% | 22.59B | | +15.37% | 14.56B | | +43.35% | 11.5B | | -8.37% | 6.93B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +10.21% | 5.36B | | -2.27% | 4.81B |
Generic Pharmaceuticals
|